A new study by researchers at the Icahn School of Medicine at Mount Sinai overturns a longstanding assumption about how mRNA ...

Silencing mRNA expression in dendritic cells did not impair T‑cell priming, including for SARS‑CoV‑2 antigens, suggesting that cross‑presentation by other cell types is sufficient to initiate immunity ...

A surprising backup system in the immune response to mRNA vaccines may hold the key to more effective cancer treatments.

In vitro transcribed mRNA has lived up to its potential as a game-changing disruptive vaccine modality during the COVID-19 ...

Messenger RNA, or mRNA, vaccine technology burst onto the scene early in the COVID pandemic, leaving many people playing catch-up on the science behind the advance. Within the first six months of ...

コロナ禍で活躍したmRNAワクチンの、さらに先へ 新型コロナウイルス（SARS-CoV-2）の世界的大流行において、mRNAワクチンは人類の叡智を結集し、前例のない速さで開発されました。この新しい技術は、パンデミックの抑制に大きく貢献した一方で、いくつかの ...

2023年のノーベル生理学・医学賞に、mRNA（メッセンジャーRNA）を用いたワクチン開発の基盤技術を開発したペンシルベニア大学の研究者2人が選ばれた。カタリン・カリコとドリュー・ワイスマンが手がけた技術は、これまでに例のないスピードで新型コロナ ...

A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...

Investing.com - German biotech company CureVac sued Moderna (NASDAQ:MRNA) in Delaware federal court on Friday, alleging that Moderna’s COVID-19 vaccine Spikevax infringed CureVac patents related to ...